Cytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial
U. Platzbecker , F. Braulke , K. Shirneshan , U. Bacher
Onkologie 39
2016
Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG)
F Theis , A. Corbacioglu , Verena I Gaidzik , Peter Paschka
Hämatologica
2017
Detection of minimal residual disease using real-time RT-PCR in MLL/AF9 Positive acute myeloid leukemia
H. Dohner , R. F. Schlenk , C. Scholl , S. Frohling
Blood 102 ( 11) 376
2003
Post-remission therapy for acute myeloid leukemia
R. F. Schlenk
Haematologica 99 ( 11) 1663 -1670
61
2014
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
P. Paschka , R. F. Schlenk , V. I. Gaidzik , J. K. Herzig
Haematologica 100 ( 3) 324 -330
119
2015
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
M.-L. Hutter-Kronke , A. Benner , K. Dohner , J. Krauter
Haematologica 101 ( 7) 839 -845
12
2016
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone
R. F. Schlenk , H. Dohner , M. Pforsich , A. Benner
British Journal of Haematology 99 ( 2) 386 -393
31
1997
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
R. F. Schlenk , D. Weber , W. Herr , G. Wulf
Leukemia 33 ( 8) 1923 -1933
6
2019
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
A. Kuendgen , M. Nomdedeu , H. Tuechler , G. Garcia-Manero
Leukemia 35 ( 3) 835 -849
42
2021
A phase Ib study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML).
J. Krauter , O. G. Ottmann , R. F. Schlenk , M. Schaich
Journal of Clinical Oncology 28
2010
Identification of Partial Tandem Duplications of the MLL Gene in Acute Myeloid Leukemia: Prospective Analysis within the Multicenter Treatment Trial AML HD98-A
K. Tobis , R. F. Schlenk , C. Liebisch , S. Fröhling
Springer, Berlin, Heidelberg 306 -311
2
2003
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
Gabriele Nagel , D Weber , E Fromm , S Erhardt
Annals of Hematology 96 ( 12) 1993 -2003
53
2017
A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.
D. Rizzieri , U. Krug , R. F. Schlenk , N. Vey
Journal of Clinical Oncology 29
3
2011
Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup
M. Schaich , R. F. Schlenk , H. K. Al-Ali , H. Dohner
Haematologica 92 ( 6) 763 -770
39
2007
Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid
S. Teichler , R. F. Schlenk , K. Strauch , N. M. Hagner
Haematologica 93 ( 7) 1105 -1107
5
2008
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia
D. Messerer , J. Engel , J. Hasford , M. Schaich
Haematologica 93 ( 6) 826 -833
53
2008
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
A. Liso , F. Castiglione , A. Cappuccio , F. Stracci
Haematologica 93 ( 8) 1219 -1226
18
2008
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
R. F. Schlenk , K. Dohner , M. Kneba , K. Gotze
Haematologica 94 ( 1) 54 -60
169
2009
Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia
A. C. Russ , S. Sander , S. C. Luck , K. M. Lang
Haematologica 96 ( 12) 1783 -1791
33
2011
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1
Eugen Tausch , Philipp Beck , Richard F. Schlenk , Billy J. Jebaraj
Haematologica 105 ( 10) 2440 -2447
4
2020